person
as of 2026-07-01Alkermes Medical Director, MD
Alkermes Medical Director
at a glance
Roles: Principal Investigator, Study Director
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Alkermes, Inc.
Roles
Principal Investigator, Study Director
Trial investigator
no
Trials led
10
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
NCT02669758Phase 3Completed
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
NCT01469039Phase 3Completed
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
NCT03187769Phase 3Completed
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
NCT02320032Phase 1Completed
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
NCT03919994—Completed
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
NCT01626456Phase 3Completed
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
NCT03201757Phase 3Completed
A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
NCT01493726Phase 1Completed
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
NCT02694328Phase 3Completed
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
NCT02873208Phase 3Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
STUDY_DIRECTOR